Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
ELMIRON (pentosan polysulfate sodium) is an oral small-molecule therapeutic approved in 1996 for interstitial cystitis/bladder pain syndrome. The mechanism of action involves reducing bladder epithelial permeability and providing a protective coating effect on the bladder urothelium. It is administered as an oral capsule and represents one of the few disease-modifying options for this chronic urological condition.
Product is in late-stage lifecycle with modest Medicare spending (~$55M annually) and approximately 47K claims, indicating a stable but niche market with limited growth opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Worked on ELMIRON at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moELMIRON represents a mature, niche-market opportunity with limited organic growth potential and minimal job creation. Roles on this product focus on risk management, safety monitoring, and defending market share against competitive and generic erosion rather than innovation or expansion.